← Mechanisms of action
ROR1
SINGLE PROTEINMus musculus
Preferred name: Tyrosine-protein kinase transmembrane receptor ROR1 ChEMBL ↗
Linked proteins
Drugs acting on this target (14)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| gnc-035 | Antagonist | experimental | mAb | ROR1 |
| cs5001 | Binding agent | experimental | mAb | ROR1 |
| NVG-111 | Binding agent | experimental | mAb | ROR1 |
| zilovertamab vedotin | Binding agent | experimental | mAb | ROR1 |
| bms-986403 | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| lyl797 | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| onct-808 | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| prgn-3007 | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| rd14-01 cell | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| ror1 car-specific autologous t-lymphocytes | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| ror1r-car-t cell | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| tils and car-tils targeting her2, mesothelin, psca, muc1, lewis-y, gpc3, axl, egfr, claudin18.2/6, ror1, gd1, or b7-h3 | Immunity, passive | experimental | Cell therapy | ROR1 immunity, passive |
| cirmtuzumab | Inhibitor | experimental | mAb | ROR1 inhibitor |
| nbe-002 | Inhibitor | experimental | mAb | ROR1 inhibitor |